[Federal Register Volume 64, Number 45 (Tuesday, March 9, 1999)]
[Notices]
[Pages 11509-11510]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 99-5750]
-----------------------------------------------------------------------
NUCLEAR REGULATORY COMMISSION
Consolidated Guidance About Materials Licenses: Program-Specific
Guidance About Commercial Radiopharmacy Licenses, Availability of Draft
NUREG
AGENCY: Nuclear Regulatory Commission (NRC).
ACTION: Notice of availability and request for comments.
-----------------------------------------------------------------------
SUMMARY: The NRC is announcing the availability of and requesting
comment on draft NUREG-1556, Volume 13, ``Consolidated Guidance about
Materials Licenses: Program-Specific Guidance about Commercial
Radiopharmacy Licenses,'' dated December 1998.
NRC is using Business Process Redesign (BPR) techniques to redesign
its materials licensing process, as described in NUREG-1539,
``Methodology and Findings of the NRC's Materials Licensing Process
Redesign.'' A critical element of the new process is consolidating and
updating numerous guidance documents into a NUREG-series of reports.
This draft NUREG report is the 13th program-specific guidance developed
to support an improved materials licensing process.
The guidance is intended for use by applicants, licensees, NRC
license reviewers, and other NRC personnel. This document combines and
updates the guidance found in ``Draft Regulatory Guide DG-0006''
(previously issued as FC 410-4), ``Guide for the Preparation of
Applications for Commercial Nuclear Pharmacy Licenses'' (March 1997),
and Standard Review Plan 85-14, ``Standard Review Plan for Applications
for Nuclear Pharmacy Licenses.'' This draft report takes a more risk-
informed, performance-based approach to licensing commercial
radiopharmacies and reduces the information (amount and level of
detail) needed to support an application to use these devices. Note
that this document is strictly for public comment and is not for use in
preparing or reviewing commercial radiopharmacy licenses until it is
published in final form. It is being distributed for comment to
encourage public participation in its development.
DATES: The comment period ends June 7, 1999. Comments received after
that time will be considered if practicable.
ADDRESSES: Submit written comments to: Chief, Rules and Directives
Branch, Division of Administrative Services, Office of Administration,
U. S. Nuclear Regulatory Commission, Washington, DC 20555-0001. Hand-
deliver comments to 11545 Rockville Pike, Rockville, Maryland, between
7:15 a.m. and 4:30 p.m. on Federal workdays. Comments may also be
submitted through the Internet by addressing electronic mail to
[email protected]
Those considering public comment may request a free single copy of
draft NUREG-1556, Volume 13, by writing to the U.S. Nuclear Regulatory
Commission, ATTN: Mrs. Sally L. Merchant, Mail Stop TWFN 9-F-31,
Washington, DC 20555-0001.
[[Page 11510]]
Alternatively, submit requests through the Internet by addressing
electronic mail to slm2@nrc.gov. A copy of draft NUREG-1556, Volume 13,
is also available for inspection and/or copying for a fee in the NRC
Public Document Room, 2120 L Street, NW. (Lower Level), Washington, DC
20555-0001.
The Presidential Memorandum dated June 1, 1998, entitled, ``Plain
Language in Government Writing,'' directed that the Federal
government's writing be in plain language. The NRC requests comments on
this licensing guidance NUREG specifically with respect to the clarity
and effectiveness of the language used. Comments should be sent to the
address listed above.
FOR FURTHER INFORMATION, CONTACT: Mrs. Sally L. Merchant, Mail Stop
TWFN 9-F-31, Division of Industrial and Medical Nuclear Safety, Office
of Nuclear Material Safety and Safeguards, U.S. Nuclear Regulatory
Commission, Washington, DC 20555, telephone (301) 415-7874; electronic
mail address: slm2@nrc.gov.
Electronic Access
Draft NUREG-1556, Vol. 13 is available electronically by visiting
NRC's Home Page (http://www.nrc.gov/NRC/nucmat.html).
Dated at Rockville, Maryland, this 3rd day of March, 1999.
For the Nuclear Regulatory Commission.
Patricia K. Holahan,
Acting Chief, Rulemaking and Guidance Branch, Division of Industrial
and Medical Nuclear Safety, NMSS
[FR Doc. 99-5750 Filed 3-8-99; 8:45 am]
BILLING CODE 7590-01-P
